1088 – Meta-Analysis: the Risk of Developing New Onset Inflammatory Bowel Disease with Interleukin-17 Blockade Therapy

2019 ◽  
Vol 156 (6) ◽  
pp. S-231
Author(s):  
Jingzhou D. Wang ◽  
Akihiro Yamada ◽  
Yuga Komaki ◽  
Fukiko Komaki ◽  
Dejan Micic ◽  
...  
PLoS ONE ◽  
2020 ◽  
Vol 15 (5) ◽  
pp. e0233781 ◽  
Author(s):  
Johan Burisch ◽  
Wolfgang Eigner ◽  
Stefan Schreiber ◽  
Daniel Aletaha ◽  
Wolfgang Weninger ◽  
...  

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Gonzalo Labarca ◽  
Lauren Drake ◽  
Gloria Horta ◽  
Michael A. Jantz ◽  
Hiren J. Mehta ◽  
...  

Abstract Introduction There is evidence of an association between inflammatory bowel disease (IBD) and lung conditions such as chronic obstructive pulmonary disease (COPD). This systematic review and meta-analysis explored the risk of new onset IBD in patients with COPD and new onset COPD in IBD patients. Methods We performed a systematic review of observational studies exploring the risk of both associations. Two independent reviewers explored the EMBASE, MEDLINE, LILACS and DOAJ databases, and the risk of bias was evaluated using the ROBBINS-I tool. Data from included studies was pooled in a random effect meta-analysis following a DerSimonian-Laird method. The quality of the evidence was ranked using GRADE criteria. Results Four studies including a pooled population of 1355 new cases were included. We found association between new onset IBD in COPD population. The risk of bias was low in most of them. Only one study reported tobacco exposure as a potential confounding factor. The pooled risk ratio (RR) for a new diagnosis of IBD in COPD patients was 2.02 (CI, 1.56 to 2.63), I2 = 72% (GRADE: low). The subgroup analyses for Crohn’s disease and ulcerative colitis yielded RRs of 2.29 (CI, 1.51 to 3.48; I2 = 62%), and 1.79 (CI, 1.39 to 2.29; I2 = 19%.), respectively. Discussion According to our findings, the risk of new onset IBD was higher in populations with COPD compared to the general population without this condition. Based on our analysis, we suggest a potential association between IBD and COPD; however, further research exploring the potential effect of confounding variables, especially cigarette smoking, is still needed. Review register (PROSPERO: CRD42018096624)


2020 ◽  
Vol 26 ◽  
Author(s):  
Yang Zhang ◽  
Dandan Li ◽  
Heng Guo ◽  
Weina Wang ◽  
Xingang Li ◽  
...  

Background: Conflicting data exist regarding the influence of thiopurines exposure on adverse pregnancy outcomes in female patients with inflammatory bowel disease (IBD). Objective: The aim of this study was to provide an up-to-date and comprehensive assessment of the safety of thiopurines in pregnant IBD women. Methods: All relevant articles reporting pregnancy outcomes in women with IBD received thiopurines during pregnancy were identified from the databases (PubMed, Embase, Cochrane Library, and ClinicalTrials.gov) with the publication data up to April 2020. Data of included studies were extracted to calculate the relative risk (RR) of multiple pregnancy outcomes: congenital malformations, low birth weight (LBW), preterm birth, small for gestational age (SGA), and spontaneous abortion. The meta-analysis was performed using the random-effects model. Results: Eight studies matched with the inclusion criteria and a total of 1201 pregnant IBD women who used thiopurines and 4189 controls comprised of women with IBD received drugs other than thiopurines during pregnancy were included. Statistical analysis results demonstrated that the risk of preterm birth was significantly increased in the thiopurine-exposed group when compared to IBD controls (RR, 1.34; 95% CI, 1.00-1.79; p=0.049; I 2 =41%), while no statistically significant difference was observed in the incidence of other adverse pregnancy outcomes. Conclusion: Thiopurines’ use in women with IBD during pregnancy is not associated with congenital malformations, LBW, SGA, or spontaneous abortion, but appears to have an association with an increased risk of preterm birth.


2021 ◽  
Vol 160 (6) ◽  
pp. S-357
Author(s):  
Jalpa Patel ◽  
Dina Fakhouri ◽  
Mohamed Noureldin ◽  
Iris Kovar-Gough ◽  
Francis A. Farraye ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document